Results 291 to 300 of about 12,125,138 (354)

A One Health Approach to Investigating Cache Valley Virus, Arkansas, USA, July 2023¹. [PDF]

Emerg Infect Dis
Carpenter A, Kojima N, Dulski TM, Calvert AE, Burkhalter KL, Ballard JR, Blount K, Fagre A, Thrasher E, Lazenby K, Hedges S, Long A, Miazgowicz K, Wood E, Owens P, Connelly CR, Gould CV, Staples JE, Rothfeldt L, Martin SW, Burke J.   +20 more
europepmc   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

Paddle leads for the treatment of nonsurgical back pain-The DISTINCT study. [PDF]

Pain Pract
Falowski S, Dorsi MJ, Heros R, Sales R, Tavel E, Lansford T, Weinand ME, Baxi N, Garber J, Forage J, Telfeian AE, Souheil H, Gilligan C, Deer T, Levy R, Jameson J, Moeschler S, Duncan J, Lim C, Desai M, Pilitsis J, Okaro U, Yue J.   +22 more
europepmc   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Safety and Efficacy of Intravenous Immune Globulin 10% (BIVIGAM^®) in Children with Primary Immune Deficiency. [PDF]

J Clin Immunol
Melamed I, Walter JE, Alpan O, BIVI 994 Authors, Leiding JW.   +4 more
europepmc   +1 more source

New Hampshire, USA

The Lancet Psychiatry, 2020
openaire   +3 more sources

National Coal Utilization Assessment: a preliminary assessment of coal utilizaton in the South. [Southern USA to 2020; forecasting]

, 1978
Luke Berry, D.J. Bjornstad, F. D. Boercker   +2 more
openalex   +2 more sources

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Corrigendum to "Inactivation of Minar2 in mice hyperactivates mTOR signaling and results in obesity" [Mol Metabol 73 (July 2023) 101744]. [PDF]

Mol Metab
Lotfollahzadeh S, Xia C, Amraei R, Hua N, Kandror KV, Farmer SR, Wei W, Costello CE, Chitalia V, Rahimi N.   +9 more
europepmc   +1 more source

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source